Article
Oncology
Jared Ostmeyer, Jason Y. Park, Mitchell S. von Itzstein, David Hsiehchen, Farjana Fattah, Mary Gwin, Rodrigo Catalan, Shaheen Khan, Prithvi Raj, Edward K. Wakeland, Yang Xie, David E. Gerber
Summary: The baseline T-cell tolerant fraction may serve as a predictor of clinically significant immune-related adverse events (irAEs) among patients receiving immune checkpoint inhibitor (ICI) therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Daniel A. Zlotoff, Malek Z. O. Hassan, Amna Zafar, Raza M. Alvi, Magid Awadalla, Syed S. Mahmood, Lili Zhang, Carol L. Chen, Stephane Ederhy, Ana Barac, Dahlia Banerji, Maeve Jones-O'Connor, Sean P. Murphy, Merna Armanious, Brian J. Forrestal, Michael C. Kirchberger, Otavio R. Coelho-Filho, Muhammad A. Rizvi, Gagan Sahni, Anant Mandawat, Carlo G. Tocchetti, Sarah Hartmann, Hannah K. Gilman, Eduardo Zatarain-Nicolas, Michael Mahmoudi, Dipti Gupta, Ryan Sullivan, Sarju Ganatra, Eric H. Yang, Lucie M. Heinzerling, Franck Thuny, Leyre Zubiri, Kerry L. Reynolds, Justine Cohen, Alexander R. Lyon, John Groarke, Paaladinesh Thavendiranathan, Anju Nohria, Michael G. Fradley, Tomas G. Neilan
Summary: In ICI myocarditis, the QRS duration is prolonged and associated with increased MACE risk, while there is no association between the QTc interval and MACE.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Feiya Ma, Jensen Vayalil, Grace Lee, Yuqi Wang, Guangyong Peng
Summary: Tumor-derived extracellular vesicles (EVs) are a major factor inducing T cell dysfunction in the tumor microenvironment, playing a crucial role in cancer immunity. By carrying immune suppressive signals, tumor-derived EVs can drive T cell dysfunction and promote tumor immunity.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Immunology
Naomi Benne, Danielle ter Braake, Arie Jan Stoppelenburg, Femke Broere
Summary: This article discusses the strategy of using nanoparticles to deliver antigens and restore immune tolerance. It highlights potential cell targets and application methods for nanoparticles, as well as how nanoparticles carrying immunomodulators can activate tolerance in other antigen-presenting cell types. It also emphasizes the importance of considering relevant factors when translating animal studies to clinical applications.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Jeffrey A. Bluestone, Brent S. McKenzie, Joshua Beilke, Fred Ramsdell
Summary: Regulatory T (Treg) cells play a crucial role in maintaining peripheral tolerance and preventing various immune-related diseases. They are able to develop in both the thymus and peripheral tissues through the expression of a transcription factor called FOXP3. Treg cells exert their tolerogenic effects by using multiple mechanisms, such as producing inhibitory cytokines, suppressing T effector cells, and modulating antigen-presenting cell function. Recently, there has been a focus on genetically engineering Treg cells to enhance their therapeutic potential, leading to ongoing clinical trials. This review highlights the advancements and challenges in harnessing Treg cells as a new approach for treating diseases.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Janine Schloeder, Fatemeh Shahneh, Franz-Joseph Schneider, Bjorn Wieschendorf
Summary: Regulatory T cells play a crucial role in immune regulation and peripheral tolerance. Current treatment strategies for autoimmune diseases focus on increasing the frequency and enhancing the function of regulatory T cells, as well as restoring the sensitivity of effector T cells to regulatory T cell-mediated suppression.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Amelie Franken, Pierre Van Mol, Sam Vanmassenhove, Elena Donders, Rogier Schepers, Thomas Van Brussel, Christophe Dooms, Jonas Yserbyt, Nico De Crem, Dries Testelmans, Walter De Wever, Kristiaan Nackaerts, Johan Vansteenkiste, Robin Vos, Stephanie Humblet-Baron, Diether Lambrechts, Els Wauters
Summary: This study utilized single-cell transcriptomics to identify the accumulation of pathogenic T-helper 17.1 cells in bronchoalveolar lavage fluid of patients with ICI-related pneumonitis. This finding explains the previous divergent research findings on the involvement of T-helper 1 and T-helper 17 in ICI-related pneumonitis, and suggests several novel potential therapeutic targets for the treatment of ICI-pneumonitis.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Zena Salih, Antonia Banyard, Joshua Tweedy, Elena Galvani, Philippa Middlehurst, Sarah Mills, John Weightman, Avinash Gupta, Paul C. Lorigan, Cong Zhou, Nathalie Dhomen, Sara Valpione, Richard Marais
Summary: This study found that immunotherapy can induce changes in the clonality and diversity of the peripheral T cell receptor repertoire in patients with melanoma. Age has an impact on treatment response, with different age groups showing different response patterns.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Katarina Pinjusic, Olivier Andreas Dubey, Olga Egorova, Sina Nassiri, Etienne Meylan, Julien Faget, Daniel Beat Constam
Summary: This study reveals that Activin-A secretion by melanoma cells inhibits adaptive antitumor immunity by indirectly inhibiting CD8(+) T cell infiltration, regardless of BRAF status. It is also found that Activin-A/INHBA expression is correlated with resistance to anti-PD1 therapy in melanoma patients and impairs response to combination anti-cytotoxic T-Lymphocyte associated protein 4/anti-PD1 treatment in preclinical models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Serena Bert, Suchita Nadkarni, Mauro Perretti
Summary: Neutrophils, while being fundamental in combating infection and injury, are now recognized as key modulators of adaptive immune responses. This review explores the novel properties of neutrophils and redefines their pathophysiological functions, highlighting their role in mediating acute inflammatory responses and regulating adaptive immunity to maintain immune tolerance.
IMMUNOLOGICAL REVIEWS
(2023)
Review
Immunology
Hanna Grasshoff, Sara Comduehr, Luisa R. Monne, Antje Mueller, Peter Lamprecht, Gabriela Riemekasten, Jens Y. Humrich
Summary: Regulatory T cells (Treg) are crucial for maintaining peripheral tolerance and controlling inflammation and autoimmunity, with the cytokine interleukin-2 (IL-2) playing a key role in their growth and survival. Many autoimmune and rheumatic diseases show disruptions in Treg biology, leading to an imbalance between protective and pathogenic immune cells. Low-dose IL-2 therapy aims to restore physiological balance by compensating for IL-2 deficiency and strengthening the Treg population to counteract inflammation effectively.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Briana Rose Halle, Allison Betof Warner, Farzana Y. Zaman, Andrew Haydon, Prachi Bhave, Anna K. Dewan, Fei Ye, Rebecca Irlmeier, Paras Mehta, Nicholas R. Kurtansky, Mario E. Lacouture, Jessica C. Hassel, Jacob S. Choi, Jeffrey A. Sosman, Sunandana Chandra, Tracey S. Otto, Ryan Sullivan, Meghan J. Mooradian, Steven T. Chen, Florentia Dimitriou, Georgina Long, Matteo Carlino, Alexander Menzies, Douglas B. Johnson, Veronica M. Rotemberg
Summary: A retrospective cohort study on patients with pre-existing psoriasis receiving ICIs for cancer treatment showed that most patients experienced psoriasis exacerbation after treatment, but it was manageable with standard therapies; some patients also experienced other immune-related adverse events; patients with disease exacerbation performed well in terms of progression-free survival compared to those who did not.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Engineering, Biomedical
Yuan Rui, Haleigh B. B. Eppler, Alexis A. A. Yanes, Christopher M. M. Jewell
Summary: During autoimmunity or organ transplant rejection, the immune system attacks host or transplanted tissue, causing inflammation. Recent advances in vaccine-based antigen-specific therapies offer promising opportunities for treating autoimmune diseases and transplant rejection. Precision and combinatorial delivery of antigens, cytokines, small molecule drugs, and immunomodulators can be facilitated by biomaterial technologies.
ADVANCED HEALTHCARE MATERIALS
(2023)
Article
Immunology
Yuantao Li, Qikai Wu, Jiancheng Lv, Junwei Gu
Summary: CDH5 is closely associated with tumor stage and prognosis in various cancers, as well as with tumor mutation burden, microsatellite instability, immune cell infiltration, and immune response genes. It shows a positive correlation with immune response and functions in promoting CD8+ T cell activity in the tumor microenvironment, suggesting its potential as a novel tumor biomarker and immune checkpoint.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Immunology
Zhanyan Gao, Yang Feng, Jinhua Xu, Jun Liang
Summary: This article reviews the research progress of T-cell exhaustion in several IMIDs and its potential application, revealing the important role of exhausted T-cells in autoimmunity and their association with favorable prognosis.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Allergy
Alexandre Le Joncour, Anne-Claire Desbois, Aurelie S. Leroyer, Edwige Tellier, Paul Regnier, Anna Maciejewski-Duval, Cloe Comarmond, Stephane Barete, Michel Arock, Patrick Bruneval, Jean-Marie Launay, Pierre Fouret, Ulrich Blank, Michelle Rosenzwajg, David Klatzmann, Mohamed Jarraya, Laurent Chiche, Fabien Koskas, Patrice Cacoub, Gilles Kaplanski, David Saadoun
Summary: This study demonstrated elevated levels of mast cell activation markers in the sera of TAK patients compared to healthy donors, along with increased mast cell expression in aortic lesions of TAK patients. Mast cells stimulated by TAK patient sera supported neoangiogenesis and fibrosis compared to healthy donor sera, indicating their key role in vascular lesions. These findings suggest mast cells may serve as a potential therapeutic target in large vessel vasculitis.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2022)
Article
Rheumatology
Anne Filleron, Tu Anh Tran, Audrey Hubert, Alexia Letierce, Guillaume Churlaud, Isabelle Kone-Paut, David Saadoun, Renaud Cezar, Pierre Corbeau, Michelle Rosenzwajg
Summary: This study found a bias towards Th17 polarization in pediatric BD patients, and Tregs can limit the differentiation of CD4(+) T cells into Th1 and Th17 cells.
Article
Immunology
Matheus Vieira, Paul Regnier, Anna Maciejewski-Duval, Alexandre Le Joncour, Guillaume Darasse-Jeze, Michelle Rosenzwajg, David Klatzmann, Patrice Cacoub, David Saadoun
Summary: This study investigates the molecular mechanisms of large-vessel involvement in giant cell arteritis (LV-GCA) by analyzing transcriptome and interferon gene signature in inflamed aortas from LV-GCA patients. The study reveals the critical involvement of pro-inflammatory signaling pathways, including interferon, JAK/STAT signaling, cytokines, and chemokines, in both aorta and T cells from LV-GCA patients. Furthermore, the study identifies a clear type I interferon signature in the aortas of LV-GCA patients and highlights the significant role of STAT3 in related gene networks. The findings suggest the potential for tailored therapeutic targeting in LV-GCA.
JOURNAL OF AUTOIMMUNITY
(2022)
Review
Psychiatry
Dominique Endres, Thomas A. Pollak, Karl Bechter, Dominik Denzel, Karoline Pitsch, Kathrin Nickel, Kimon Runge, Benjamin Pankratz, David Klatzmann, Ryad Tamouza, Luc Mallet, Marion Leboyer, Harald Pruess, Ulrich Voderholzer, Janet L. Cunningham, Katharina Domschke, Ludger Tebartz van Elst, Miriam A. Schiele
Summary: This conceptual review paper summarizes the clinical manifestations, pathophysiological considerations, diagnostic investigations, and treatment approaches of immune-related secondary OCD. The novel concept of autoimmune OCD is proposed for a small subgroup of OCD patients, and clinical signs based on the PANDAS/PANS criteria and from recent experience with autoimmune encephalitis and autoimmune psychosis are suggested. Red flag signs for autoimmune OCD include (sub)acute onset, unusual age of onset, atypical presentation of OCS with neuropsychiatric features or accompanying neurological symptoms, autonomic dysfunction, treatment resistance, associations of symptom onset with infections such as group A streptococcus, comorbid autoimmune diseases or malignancies. Clinical investigations may also reveal alterations such as increased levels of anti-basal ganglia or dopamine receptor antibodies or inflammatory changes in the basal ganglia in neuroimaging. Based on these red flag signs, the criteria for a possible, probable, and definite autoimmune OCD subtype are proposed.
TRANSLATIONAL PSYCHIATRY
(2022)
Article
Immunology
Paul Engeroff, Aude Belbezier, Antoine Monsel, David Klatzmann
Summary: This study evaluated the therapeutic potential of interleukin (IL)-1 blockade using Anakinra in a mouse model of lipopolysaccharide (LPS)-induced acute lung injury (ALI). The results showed that Anakinra treatment reduced weight loss induced by ALI, decreased inflammatory cytokines levels, and reduced leukocyte infiltration. After nine days of treatment, mice treated with Anakinra displayed lower levels of leukocytes and alveolar macrophages in bronchoalveolar lavage fluids.
IMMUNITY INFLAMMATION AND DISEASE
(2022)
Review
Psychiatry
Pierre Ellul, Eric Acquaviva, Hugo Peyre, Michelle Rosenzwajg, Pierre Gressens, David Klatzmann, Richard Delorme
Summary: This study investigates the association between autoimmune or inflammatory disorders (AID) in parents and the risk of neurodevelopmental disorders (NDD) in their children. The results show that mothers and fathers with AID are associated with an increased risk of Autism Spectrum Disorder (ASD) and Attention-Deficit Hyperactivity Disorder (ADHD) in their offspring, but the strength of this association varies in AID-specific analyses.
TRANSLATIONAL PSYCHIATRY
(2022)
Article
Immunology
Bertrand Bellier, Alicia Saura, Lucas A. Lujan, Cecilia R. Molina, Hugo D. Lujan, David Klatzmann
Summary: Developed a thermostable orally administered vaccine that induces a robust mucosal immune response and provides complete protection against SARS-CoV-2 in mice and hamsters.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Lee S. Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, Baptiste Abbar, Bruno Pinna, Yves Allenbach, Jean-Paul Mira, Javid Moslehi, Michelle Rosenzwajg, Joe-Elie Salem
Summary: This article describes a case in which nearly lethal immune-checkpoint inhibitor (ICI)-induced myocarditis was reversed by the treatment of abatacept with adjusted dosage. This provides a basis for personalized treatment of patients with severe ICI adverse events.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Immunology
Valerie Pourcher, Lisa Belin, Cathia Soulie, Michelle Rosenzwajg, Stephane Marot, Karine Lacombe, Nadia Valin, Gilles Pialoux, Ruxandra Calin, Christia Palacios, Isabelle Malet, Karen Zafilaza, Roland Tubiana, Marc-Antoine Valantin, David Klatzmann, Vincent Calvez, Noemie Simon-Tillaux, Anne-Genevieve Marcelin
Summary: This study assessed the humoral responses to the SARS-CoV-2 Delta-variant in people with HIV after BNT162b2 vaccination. The results showed high seroconversion rates and comparable neutralization rates against the Delta variant as compared to the D61G strain.
Article
Rheumatology
Jens Y. Humrich, Patrice Cacoub, Michelle Rosenzwajg, Fabien Pitoiset, Hang Phuong Pham, Joel Guidoux, David Leroux, Thomas Vazquez, Gabriela Riemekasten, Josef S. Smolen, George Tsokos, David Klatzmann
Summary: Low-dose IL-2 therapy shows efficacy in patients with moderate-to-severe active systemic lupus erythematosus (SLE), but further research is needed.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Marie Binvignat, Gabriel Pires, Nicolas Tchitchek, Felicie Costantino, Alice Courties, David Klatzmann, Atul J. Butte, Bernard Combe, Maxime Dougados, Pascal Richette, Encarnita Mariotti-Ferrandiz, Francis Berenbaum, Jeremie Sellam
Summary: This study aimed to classify phenotypes in hand osteoarthritis (HOA) based on cardinal symptoms. Using the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) subscores and visual analog scale, a hierarchical agglomerative clustering analysis was performed on data from the Digital Cohort Design (DIGICOD). Five clusters were identified, indicating different levels of symptoms and associations with joint destruction and physical/psychological burden.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Alexandre Le Joncour, Paul Regnier, Anna Maciejewski-Duval, Erwan Charles, Stephane Barete, Pierre Fouret, Michelle Rosenzwajg, David Klatzmann, Patrice Cacoub, David Saadoun
Summary: This study aimed to investigate the effect of phosphodiesterase 4 (PDE4) inhibition on neutrophil activation in Behcet's disease (BD). The results showed that surface markers, reactive oxygen species (ROS) production, and neutrophil extracellular traps (NETs) production were upregulated in BD patient neutrophils. Inhibition of PDE4 significantly reduced neutrophil surface activation markers, ROS production, NETosis, and genes and pathways related to innate immunity, intracellular signaling, and chemotaxis.
ARTHRITIS & RHEUMATOLOGY
(2023)
Meeting Abstract
Immunology
Aixin Yu, Alejandro Moro, Michelle Rosenzwajg, Nicolas Tchitchet, David Klatzmann, Thomas R. Malek
JOURNAL OF IMMUNOLOGY
(2022)
Article
Critical Care Medicine
Antoine Monsel, Caroline Hauw-Berlemont, Miryam Mebarki, Nicholas Heming, Julien Mayaux, Otriv Nguekap Tchoumba, Jean-Luc Diehl, Alexandre Demoule, Djillali Annane, Clemence Marois, Sophie Demeret, Emmanuel Weiss, Guillaume Voiriot, Muriel Fartoukh, Jean-Michel Constantin, Bruno Megarbane, Gaetan Plantefeve, Stephanie Malard-Castagnet, Sonia Burrel, Michelle Rosenzwajg, Nicolas Tchitchek, Helene Boucher-Pillet, Guillaume Churlaud, Audrey Cras, Camille Maheux, Chloe Pezzana, Mamadou Hassimiou Diallo, Jacques Ropers, Philippe Menasche, Jerome Larghero
Summary: The efficacy of UC-MSCs in patients with SARS-CoV-2-induced ARDS was assessed in this study. The results showed no significant difference in respiratory indicators between the UC-MSCs and placebo groups. The repeated UC-MSCs infusions did not lead to any serious adverse events during treatment or thereafter.